To assess the efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy for early-stage triple-negative breast cancer (TNBC) patients with different clinical characteristics. Randomized clinical trials for PD-1/PD-L1 inhibitors and chemotherapy combination were included. Pooled analysis of odds ratio (OR) for pathological complete response (pCR) and hazard ratio (HR) for event-free survival (EFS) was conducted overall and for predefined subgroups. The combination of immunotherapy and chemotherapy significantly improved pCR rate in early TNBC patients (OR, 1.77), and the incidence of events was significantly reduced by 37%. Lymph node metastasis was associated with more benefits on pCR (OR[N0], 1.29; OR[N+], 2.57; P = 0.01), while earlier T stage was related to more benefits on EFS (HR[T1-T2], 0.48; HR[T3-T4], 0.85; P = 0.05). The addition of PD-1/PD-L1 inhibitors to chemotherapy offers improved pCR and EFS in early TNBC patients. T and N stages may have implications for the efficacy.

中文翻译：

---

使用 PD-1/PD-L1 抑制剂治疗早期三阴性乳腺癌患者的疗效和预后相关的临床特征：荟萃分析

评估PD-1/PD-L1抑制剂联合化疗对不同临床特征的早期三阴性乳腺癌（TNBC）患者的疗效。包括 PD-1/PD-L1 抑制剂和化疗联合的随机临床试验。对病理完全缓解 (pCR) 的比值比 (OR) 和无事件生存 (EFS) 的风险比 (HR) 进行了总体分析和预定义亚组的汇总分析。免疫治疗与化疗相结合显着提高了早期TNBC患者的pCR率（OR，1.77），事件发生率显着降低了37%。淋巴结转移与 pCR 的更多益处相关（OR[N0]，1.29；OR[N+]，2.57；P = 0.01），而 T 分期较早与 EFS 的更多益处相关（HR[T1-T2]，0.48） ；HR[T3-T4]，0.85；P = 0.05）。在化疗中添加 PD-1/PD-L1 抑制剂可以改善早期 TNBC 患者的 pCR 和 EFS。T 和 N 阶段可能会对疗效产生影响。